The discovery of the association between EGFR mutations and the efficacy of EGFR tyrosine-
kinase inhibitors (TKIs) has revolutionized the treatment paradigm for patients with non …

Colorectal cancer (CRC) is the second leading cause of cancer-related death worldwide.
Therefore, the need for new therapeutic strategies is still a challenge. Surgery and …

Lung adenocarcinoma (LUAD), commonly driven by KRAS mutations, is responsible for 7%
of all cancer mortality. The first allele-specific KRAS inhibitors were recently approved in …

Mismatch repair (MMR)-deficient cancer evolves through the stepwise erosion of coding
homopolymers in target genes. Curiously, the MMR genes MutS homolog 6 (MSH6) and …

Mutational patterns caused by APOBEC3 cytidine deaminase activity are evident throughout
human cancer genomes. In particular, the APOBEC3A family member is a potent genotoxin …

Two APOBEC DNA cytosine deaminase enzymes, APOBEC3A and APOBEC3B, generate
somatic mutations in cancer, thereby driving tumour development and drug resistance. Here …

Gemcitabine is a widely used chemotherapy drug that acts by targeting DNA replication.
Understanding why many tumors are unresponsive to gemcitabine is a clinical challenge. A …

The majority of EGFR mutant lung adenocarcinomas respond well to EGFR tyrosine kinase
inhibitors (TKI). However, most of these responses are partial, with drug-tolerant residual …

APOBEC3 cytidine deaminases have emerged as key drivers of mutagenesis in a wide
spectrum of tumor types and are now appreciated to play a causal role in driving tumor …

Simple Summary APOBEC cytosine deaminases represent potent mutational sources in
over 50% of human cancers and are linked to tumor heterogeneity and therapy responses …